Evaluation of a new point-of-care celite-activated clotting time analyzer in different clinical settings: The i-STAT celite-activated clotting time test

Anesthesiology

Volumn 99, Issue 1, 2003, Pages 54-59

  Paniccia, Rita ^a,d   Fedi, Sandra ^a   Carbonetto, Fiorella ^b   Noferi, Daniela ^b   Conti, Paolo ^c   Bandinelli, Brunella ^a   Giusti, Betti ^a   Evangelisti, Lucia ^a   Pretelli, Paola ^b   Palmarini, Mara F G ^b   Abbate, Rosanna ^a   Prisco, Domenico ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Unita Operativa Anestesiol R 1   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d Sez Clin Med Gen Clin Spec   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; AGED; ANALYZER; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPARINIZATION; HUMAN; INTERMETHOD COMPARISON; MALE; PATIENT MONITORING; PRIORITY JOURNAL;

AGED; ANTICOAGULANTS; BLOOD COAGULATION TESTS; CARDIAC SURGICAL PROCEDURES; DIATOMACEOUS EARTH; ELECTROCARDIOGRAPHY; FEMALE; HEPARIN; HUMANS; MALE; POINT-OF-CARE SYSTEMS; RENAL DIALYSIS; UREMIA; WHOLE BLOOD COAGULATION TIME;

EID: 0038787664     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200307000-00012     Document Type: Article

References (31)

1. Despotis GJ, Gravlee G, Filos K, Levy J: Anticoagulation monitoring during cardiac surgery: A review of current and emerging techniques. ANESTHESIOLOGY 1999; 91:1122-51
2. Hattersley PG: Activated coagulation time of whole blood. JAMA 1966; 96:150-4
3. Doty DB, Knott HW, Hoyt JL, Koepke JA: Heparin dose for accurate anticoagulation in cardiac surgery. J Cardiovasc Surg 1979; 20:597-604
4. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, Cox JL, Lappas DG: Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994; 108:1076-82
5. Murray DJ, Brosnahan WJ, Pennell B, Kapalanski D, Weiler JM, Olson J: Heparin detection by the activated coagulation time: A comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth 1997; 11:24-8
6. Muller-Plathe O, Ginzbourg J, Rudolph S: Evaluation of the i-STAT portable blood gas and electrolyte analyser. J Lab Med 1997; 21:325-31
7. Bingham D, Kendall J, Clancy M: The portable laboratory: An evaluation of the accuracy and reproducibility of I-STAT. Ann Clin Biochem 1999; 36:66-71
8. Schneuwly OD, Reber G, De Moerloose P: Celite ACT measurement: Comparison of i-STAT®, a new assay system, with conventional Hemochron® (abstract). Thromb Haemost 2001; July(suppl):Abstract P679
9. Paniccia R, Carbonetto F, Bandinelli B, Palmarini MFG, Conti P, Fedi S, Lari B, Lenti M, Rossi L, Abbate R, Prisco D: Monitoring heparin treatment in different clinical settings: Comparison of two point-of-care whole blood coagulation analysers (abstract). Haematologica 2002; 87:89
10. Teien AN, Lie M: Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10:399-410
11. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurements. Lancet 1986; 1:307-10
12. Bland JM, Altman DG: Comparing methods of measurements: Why plotting difference against standard method is misleading. Lancet 1995; 346:1085-7
13. Bull BS, Korpman RA, Huse WM, Briggs BD: Heparin therapy during extracorporeal circulation: I. Problems in existing heparin protocols. J Thorac Cardiovasc Surg 1975; 69:674-84
14. Bull BS, Huse WM, Brauer FS, Korpman RA: Heparin therapy during extracorporeal circulation: II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975; 69:685-9
15. Cohen M: Monitoring anticoagulation during percutaneous coronary interventions. J Thromb Thrombolysis 1995; 1:285-288
16. Seifert R, Borchert W, Letendre P, Knutson R, Cipolle R: Heparin kinetics during hemodialysis: Variation in sensitivity, distribution volume, and dosage. Ther Drug Monit 1986;8:31-6
17. Culliford AT, Gitel SN, Starr N, Thomas ST, Baumann FG, Wessler S, Spencer FC: Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981; 193:105-11
18. Despotis GJ, Levine V, Joiner-Maier D, Joist JH: A comparison between continuous infusion versus standard bolus administration of heparin based on monitoring in cardiac surgery. Blood Coagul Fibrinolysis 1997; 8:419-30
19. Cohen EJ, Camerlengo LJ, Dearing JP: Activated clotting time and CPB: I. The effect of haemodilution and hypothermia upon the activated clotting time. J Extra Corpor Technol 1980; 12:139-141
20. Kmiecik SA, Liu JL, Vaadia TS, Nichols JD, Kohtz RJ, Mills NJ, Petterson A: Quantitative evaluation of hypothermia, hyperthermia, and hemodilution on coagulation. J Extra Corpor Technol 2001; 33:100-5
21. Wendell HP: Prolongation of the activated clotting time with aprotinin depends on the type of activator. Blood Coagul Fibrinolysis 1993; 4:41-5
22. Despotis GJ, Filos KS, Levine V, Alsoufiev A, Spitznagel E: Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro. Anesth Analg 1996; 82:1126-31
23. Gravlee GP, Whitaker CL, Mark LJ: Baseline activated clotting time should be measured after surgical incision. Anesth Analg 1984; 63:394-8
24. Levy JH, Monte F, Szlam F, Hillyer CD: The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000; 90:1076-9
25. Leyvi G, Shore-Lesserson L, Harrington D, Vela-Cantos F, Hossain S: An investigation of a new activated clotting time "MAX-ACT" in patients undergoing extracorporeal circulation. Anesth Analg 2001; 92:578-83
26. Despotis GJ, Joist JH: Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: An update. J Cardiothorac Vasc Anesth 1999; 13:18-29
27. Knudsen L, Hasenkam JM, Kure HH, Hughes P, Bellaiche L, Ahlburg P, Djurhuus C: Monitoring thrombin generation with prothrombin fragment 1+2 assay during cardiopulmonary bypass surgery. Thromb Res 1996; 84:45-54
28. Gil W: Inflammo-coagulatory response, extrinsic pathway thrombin generation and a new theory of activated clotting time interpretation. Perfusion 2001; 16:27-35
29. Heller EL, Paul L: Anticoagulation management in a patient with acquired antithrombin III deficiency. J Extra Corpor Technol 2001; 33:245-8
30. Lemmer JH, Despotis GJ: Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002; 123:213-7
31. Bode AP, Castellani WJ, Hodges ED, Yelverton S: The effect of lysed platelets on neutralization of heparin in vitro with protamine as measured by the activated coagulation time. Thromb Haemost 1991; 66:213-7